Coloplast Dirección

Dirección controles de criterios 4/4

El CEO de Coloplast's es Kristian Villumsen , nombrado en Dec 2018, tiene una permanencia de 5.33 años. compensación anual total es DKK23.30M, compuesta por 51.5% salario y 48.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.045% de las acciones de la empresa, por valor de €11.74M. La antigüedad media del equipo directivo y de la junta directiva es de 6 años y 6.3 años, respectivamente.

Información clave

Kristian Villumsen

Chief Executive Officer (CEO)

kr.23.3m

Compensación total

Porcentaje del salario del CEO	51.5%
Permanencia del CEO	5.4yrs
Participación del CEO	0.05%
Permanencia media de la dirección	6.1yrs
Promedio de permanencia en la Junta Directiva	6.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Kristian Villumsen en comparación con los beneficios de Coloplast?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	kr.5b
Dec 31 2023	n/a	n/a	kr.5b
Sep 30 2023	kr.23m	kr.12m	kr.5b
Jun 30 2023	n/a	n/a	kr.5b
Mar 31 2023	n/a	n/a	kr.5b
Dec 31 2022	n/a	n/a	kr.5b
Sep 30 2022	kr.21m	kr.12m	kr.5b
Jun 30 2022	n/a	n/a	kr.5b
Mar 31 2022	n/a	n/a	kr.5b
Dec 31 2021	n/a	n/a	kr.5b
Sep 30 2021	kr.22m	kr.11m	kr.5b
Jun 30 2021	n/a	n/a	kr.5b
Mar 31 2021	n/a	n/a	kr.4b
Dec 31 2020	n/a	n/a	kr.4b
Sep 30 2020	kr.20m	kr.11m	kr.4b
Jun 30 2020	n/a	n/a	kr.4b
Mar 31 2020	n/a	n/a	kr.4b
Dec 31 2019	n/a	n/a	kr.4b
Sep 30 2019	kr.17m	kr.10m	kr.4b
Jun 30 2019	n/a	n/a	kr.4b
Mar 31 2019	n/a	n/a	kr.4b
Dec 31 2018	n/a	n/a	kr.4b
Sep 30 2018	kr.11m	kr.6m	kr.4b
Jun 30 2018	n/a	n/a	kr.4b
Mar 31 2018	n/a	n/a	kr.4b
Dec 31 2017	n/a	n/a	kr.4b
Sep 30 2017	kr.10m	kr.6m	kr.4b

Compensación vs. Mercado: La compensación total de Kristian($USD3.35M) está por debajo de la media de empresas de tamaño similar en el mercado German ($USD5.57M).

Compensación vs. Ingresos: La compensación de Kristian ha sido consistente con los resultados de la empresa en el último año.

CEO

Kristian Villumsen (53 yo)

5.4yrs

Permanencia

kr.23,300,000

Compensación

Mr. Kristian Villumsen has been Independent Director of Demant A/S since March 5, 2021. He has been the President and Chief Executive Officer of Coloplast A/S since December 4, 2018. Mr. Villumsen was an E...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Kristian Villumsen	President & CEO	5.4yrs	kr.23.30m	0.045% DKK 11.5m
Anders Lonning-Skovgaard	Executive VP & CFO	9.8yrs	kr.11.90m	0.0012% DKK 300.6k
Allan Rasmussen	Executive Vice President of Global Operations	9.8yrs	kr.10.50m	0% DKK 0
Nicolai Andersen	Executive Vice President of Innovation	no data	kr.10.00m	sin datos
Paul Marcun	Executive Vice President of Growth	5.3yrs	kr.12.00m	sin datos
Thomas Barfod	Senior Controller & Employees Representative Director	no data	kr.450.00k	0.000020% DKK 5.1k
Ellen Bjurgert	Vice President of Investor Relations	7.6yrs	sin datos	sin datos
Dennis Kaysen	Director of Corporate Communications	no data	sin datos	sin datos
Dorthe Ronnau	Senior Vice President of People & Culture	2.3yrs	sin datos	sin datos
Alain Morvan	Senior Vice President of Sales Europe	12.1yrs	sin datos	sin datos
Rasmus Møller	Senior Vice President of Wound & Skin Care	3.7yrs	sin datos	sin datos
Manu Varma	Senior Vice President of Chronic Care - North America	6.1yrs	sin datos	sin datos

6.1yrs

Permanencia media

54yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de CBHD es experimentado (6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Thomas Barfod	Senior Controller & Employees Representative Director	18.3yrs	kr.450.00k	0.000020% DKK 5.1k
Carsten Hellmann	Independent Director	6.4yrs	kr.690.00k	0.0027% DKK 680.2k
Lars Rasmussen	Chairman of the Board	5.4yrs	kr.1.84m	0.092% DKK 23.5m
Niels Louis-Hansen	Deputy Chairman	56.3yrs	kr.938.00k	1.93% DKK 491.3m
Marianne Wiinholt	Independent Director	3.4yrs	kr.880.00k	0.00022% DKK 56.0k
Jette Nygaard-Andersen	Independent Director	8.4yrs	kr.600.00k	sin datos
Nikolaj Gundersen	Employees Representative Director	6.3yrs	kr.450.00k	sin datos
Roland Pedersen	Employees Representative Director	6.3yrs	kr.450.00k	0.00072% DKK 183.4k
Annette Bruls	Independent Director	2.4yrs	kr.600.00k	sin datos

6.3yrs

Permanencia media

58yo

Promedio de edad

Junta con experiencia: La junta directiva de CBHD se considera experimentada (6.3 años de antigüedad promedio).

Coloplast Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Deputy Chairman recently bought €5.4m worth of stock

Less than half of directors are independent

Coloplast Announces Executive Changes

Less than half of directors are independent

Contraline Names Yelena Tropsha as CTO

Coloplast A/S Elects Marianne Wiinholt as A New Member of the Board of Directors

Recent updates

First half dividend of kr.5.00 announced

Coloplast A/S Revises Earnings Guidance for the Fiscal Year 2023/24

New major risk - Financial position

Second quarter 2024 earnings released: EPS: kr.5.57 (vs kr.5.44 in 2Q 2023)

First quarter 2024 earnings released

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Coloplast A/S Approves the Distribution of Year-End Dividend

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Now 21% undervalued after recent price drop

Full year 2023 earnings released

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Deputy Chairman recently bought €5.4m worth of stock

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

New minor risk - Shareholder dilution

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Third quarter 2023 earnings released: EPS: kr.5.99 (vs kr.6.07 in 3Q 2022)

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

First quarter 2023 earnings released: EPS: kr.5.31 (vs kr.5.67 in 1Q 2022)

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

Upcoming dividend of kr.15.00 per share

Less than half of directors are independent

Coloplast Announces Executive Changes

Full year 2022 earnings released: EPS: kr.22.17 (vs kr.22.67 in FY 2021)

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

Coloplast Launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023

Third quarter 2022 earnings released

Coloplast A/S Provides Revenue Guidance for the Fiscal Year 2021-2022

Coloplast A/S Provides Earnings Guidance for the Full Year of 2022

Second quarter 2022 earnings released

Less than half of directors are independent

Contraline Names Yelena Tropsha as CTO

Coloplast A/S (CPSE:COLO B) completed the acquisition of Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners.

First quarter 2022 earnings: Revenues exceed analyst expectations

Coloplast A/S Updates Earnings Guidance for the Year 2021/22

Independent Director Birgitte Nielsen has left the company

Upcoming dividend of kr.14.00 per share

Full year 2021 earnings released: EPS kr.22.67 (vs kr.19.74 in FY 2020)

Third quarter 2021 earnings released: EPS kr.5.89 (vs kr.4.69 in 3Q 2020)

Coloplast A/S Provides Earnings Guidance for the Year 2020/2021

Coloplast A/S Provides Earnings for the Year 2021

Second quarter 2021 earnings released

New 90-day low: €117

First quarter 2021 earnings released

Revenue beats expectations

New 90-day high: €136

New 90-day low: €119

Coloplast A/S Elects Marianne Wiinholt as A New Member of the Board of Directors

Upcoming Dividend of kr.13.00 Per Share

New 90-day low: €122

Coloplast A/S (CPSE:COLO B) acquired Nine Continents Medical, Inc. for approximately $150 million.

Revenue misses expectations

New 90-day low: €128

New 90-day low: €130

New 90-day low - €132

Coloplast A/S to Report First Half, 2021 Results on May 06, 2021

Earnings released

New 90-day low - €137

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad